Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia
Eli Lilly (NYSE: LLY) China has announced a strategic partnership with JD Health (HKG: 6618)...
Fineline Cube
Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its oral primary biliary cholangitis (PBC) treatment,...
Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
JCBio & MGI Launch Korea’s First DCS Lab to Accelerate Multi‑Omics Innovation
South Korean biotechnology firm JCBio and global genomics leader MGI Tech Co., Ltd. today signed...
IVD Medical Acquires 20 % of GoFintech in HK$3.14 B Deal
IVD Medical Holding Limited (HKG: 1931) disclosed that it will purchase 1,848,496,429 shares of GoFintech...
Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has...
Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria
Shanghai Shenlian Biomedical Co., Ltd. (Shenlian Bio, SHA: 688098) announced that its licensed innovative drug,...
Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced on September 1 that the National Medical...
Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the U.S. Food and Drug Administration...
Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the Drug Regulatory Authority of Pakistan...
Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) presented compelling real‑world evidence from the STEER...
Eisai & Biogen Secure FDA Approval for Lecanemab Auto‑Injector – Home‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) announced that the U.S. Food and...
PackGene & CMRI Announce AAV Screening Kit for Global Gene Therapy R&D
PackGene LLC, a global leader in gene‑therapy contract development and manufacturing, and the Children’s Medical...
Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment
Suzhou HemaCell Therapeutics, a platelet‑regeneration‑focused cell‑therapy developer, announced that the Center for Drug Evaluation (CDE)...
Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended...
Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains
Luye Pharma Group Ltd. (HKG: 2186) on Aug. 28, 2025 released its financial performance for...
Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge
Shanghai Pharmaceutical Holding Co., Ltd. (SHA: 601607, HKG: 2607) on Aug. 28, 2025 announced its...
Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
Zennova Pharmaceuticals Group and Rapafusyn Pharmaceuticals on Aug. 28, 2025 announced a strategic collaboration to...
Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...
Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
China-based Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi‑annual financial results for...